Skip to main content
Episurf logo

Episurf — Investor Relations & Filings

Ticker · EPIS ISIN · SE0003491562 LEI · 549300GORBCSMHZB2J75 ST Manufacturing
Open in API
Filings indexed 873 across all filing types
Latest filing 2020-02-07 Earnings Release
Country SE Sweden
Listing ST EPIS

About Episurf

https://episurf.com/

Episurf is a medical device company that develops and commercializes patient-specific solutions for treating painful joint injuries. The company's core technology utilizes 3D imaging to create personalized orthopedic implants and surgical instruments tailored to each patient's unique anatomy and cartilage defect. Its primary product line, the Episealer® system, provides minimally invasive implants for treating cartilage and underlying bone lesions in the knee and ankle joints. The objective of this individualized approach is to repair the joint, alleviate pain, and restore function, offering a treatment option for patients, often middle-aged, who are not yet candidates for total joint replacement surgery.

Recent filings

Filing Released Lang Actions
Earnings Release 2019
Earnings Release Classification · 1% confidence The document is titled "Bokslutskommuniké 1 oktober – 31 december 2019" (Year-end report/Financial statement release for October 1 – December 31, 2019) and contains detailed financial summaries for the fourth quarter and the full fiscal year 2019, including net sales, gross order intake, net result, and earnings per share. It also includes management commentary ("Vd ordet") and detailed financial information (Nettoomsättning och resultat, Finansiell ställning). This structure strongly indicates a comprehensive financial report covering a full fiscal year, which aligns with the definition of an Annual Report (10-K), although the specific Swedish term 'Bokslutskommuniké' often corresponds to the content of a 10-K or a detailed year-end financial statement release. Given the comprehensive nature covering the entire fiscal year and detailed financial tables, it is classified as an Annual Report (10-K). If it were only a quarterly report, 'IR' would be more appropriate, but the inclusion of 'Räkenskapsåret 2019' (Fiscal year 2019) points to the annual filing. Q4 2019
2020-02-07 Swedish
Interim / Quarterly Report 2019
Interim / Quarterly Report Classification · 1% confidence The document is a 'Year-end report' for the period 1 October – 31 December 2019. It contains comprehensive financial statements, including net sales, operating profit/loss, cash flow, and balance sheet data for both the Group and the Parent Company. It also includes a CEO message, business updates, and detailed financial analysis. Since it covers a period shorter than a full fiscal year (Q4) and provides substantive financial data, it is classified as an Interim/Quarterly Report. Q4 2019
2020-02-07 English
Nytt patentbeviljande i USA för Episurf Medical
Regulatory Filings Classification · 1% confidence The document announces that the USPTO intends to grant a new patent to Episurf Medical regarding a system and method for creating decision support material for joint damage assessment. It is a specific announcement about intellectual property/patents. This type of announcement, which is not a standard financial report (10-K, IR, ER) or a management change (MANG), fits best under the general category for specific regulatory or corporate updates that aren't covered elsewhere. Since it is a specific corporate announcement regarding intellectual property, and there is no specific code for 'Patent Grant Announcement', it should be classified as a general Regulatory Filing (RNS), as it is a mandatory disclosure under EU market abuse regulation ('EU:s marknadsmissbruksförordning').
2020-01-31 Swedish
New US patent approval for Episurf Medical
Regulatory Filings Classification · 1% confidence The document announces the receipt of a 'Notice of Allowance' from the USPTO for a new patent related to joint lesion assessment. It is a brief press release format, not a comprehensive financial report (like 10-K or IR). It does not fit the definitions for AGM-R, 10-K, AR, MANG, CT, CAP, DVA, DLST, DIRS, ER, SR, FS, CGR, IRAT, LTR, TAR, MRQ, NAV, DIV, DEF 14A, RPA, SHA, or POS. It is not a dividend announcement, management change, or earnings release. Since it is a specific regulatory/legal update regarding intellectual property (a patent approval), and it doesn't fit the other specific categories, it falls best under the general 'Regulatory Filings' category, which serves as a fallback for miscellaneous official announcements not covered elsewhere. Given the context of a patent approval, it is a form of official regulatory news.
2020-01-31 English
Episurf Medical receives CE mark for Episealer® Talus and Talus Osteotomy Guide
Regulatory Filings Classification · 1% confidence The document is a short announcement from Episurf Medical stating that the company has received a CE mark for its Episealer® Talus and Talus Osteotomy Guide. It includes quotes from the CEO and Medical Advisor regarding the significance of this regulatory approval and commercial opportunity. The final paragraph explicitly states: "This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation." This structure—a brief announcement of a significant event (regulatory approval) that is mandatory to disclose—fits best under the general category for regulatory announcements that don't fit specific financial reporting codes. Since it is not a financial report (10-K, IR, ER), a management change (MANG), or a director's trade (DIRS), the most appropriate classification is Regulatory Filings (RNS), which serves as the general category for mandatory disclosures not covered elsewhere.
2020-01-08 English
Episurf Medical erhåller CE-godkännande för Episealer® Talus och Talus Osteotomiguide
Regulatory Filings Classification · 1% confidence The document is a short press release written in Swedish announcing that Episurf Medical has received CE approval for two new medical devices (Episealer® Talus and Talus Osteotomiguide). It includes quotes from the CEO and Medical Advisor, and standard 'About Us' information. Crucially, the final paragraph states: "Denna information är sådan information som Episurf Medical AB är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning" (This information is such information that Episurf Medical AB is obliged to make public pursuant to the EU's Market Abuse Regulation). This indicates a mandatory regulatory disclosure. Since the content is a specific announcement (product approval/market access) that doesn't fit perfectly into the defined categories like 10-K, ER, or DIV, and it is a general regulatory disclosure, the most appropriate fallback category is Regulatory Filings (RNS). The document is short and is an announcement, not the full report itself.
2020-01-08 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.